Bausch Health Reports Strong FY2025 Operational Growth, Issues 2026 Guidance
BHC sits 41% above its 52-week low of $4.25.
Summary
Bausch Health announced its fourth quarter and full-year 2025 financial results, reporting significant revenue and Adjusted EBITDA growth for the full year, exceeding internal guidance, alongside new 2026 financial outlook.
Key Events · Earnings and Guidance · BHC
-
Full-Year 2025 Performance Exceeds Guidance
Consolidated revenues grew 7% to $10.27 billion, and Adjusted EBITDA increased 7% to $3.54 billion for the full year 2025, exceeding prior guidance for the Bausch Health (excluding Bausch + Lomb) segment.
-
Mixed Q4 2025 Financial Results
Reported Q4 revenues of $2.80 billion (up 9%), but a GAAP net loss of $112 million (compared to $93 million net income in Q4 2024) and a $145 million goodwill impairment related to its Generics business unit.
-
Provides 2026 Financial Outlook
Issued full-year 2026 guidance projecting revenues of $10.625-$10.875 billion and Adjusted EBITDA of $3.875-$4.000 billion, indicating continued modest growth.
-
Significant Debt Refinancing Efforts
Completed a $1.7 billion debt exchange offer during Q4 2025, contributing to $9.6 billion in total refinancing for the full year, successfully extending near- and medium-term maturities.
Analysis · BHC · Life Sciences
Bausch Health's full-year 2025 results demonstrate strong operational execution, with both revenue and Adjusted EBITDA exceeding previous guidance, particularly for the Bausch Health (excluding Bausch + Lomb) segment. The successful refinancing of $9.6 billion in debt throughout 2025 significantly improves the company's maturity profile, addressing a key concern for investors. While the fourth quarter saw a GAAP net loss and a goodwill impairment charge, these were offset by robust adjusted earnings and positive forward guidance for 2026, signaling continued growth. The initiation of a Phase 3 trial for Larsucosterol is a positive R&D development, though the previously announced RED-C program failure remains a setback. Investors should monitor the company's ability to sustain operational growth, manage its debt, and advance its pipeline.
At the time of this filing, BHC was trading at $6.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $4.25 to $8.69. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.